Sweden’s Elekta Q4 operating profit beats expectations at SEK 902 mln

Elekta beat adjusted EBIT expectations at SEK 902 million versus SEK 811 million consensus, and the adjusted EBIT margin improved to 18.9% from 16.2% expected. However, order intake was a major miss at SEK 4.57 billion versus SEK 5.83 billion expected, and net sales of SEK 4.76 billion and adjusted EPS of SEK 0.57 also fell short. For FY2026/27, the company expects constant-currency sales growth and EBIT margin improvement, while maintaining its SEK 2.40 dividend.

Analysis

Elekta’s print looks less like a clean demand recovery and more like a margin/operations reset story that is now close to fully reflected in the base. The key tell is that profitability improved despite weak order intake, which usually means the benefit is coming from cost actions, mix, and accounting normalization rather than a sustainable acceleration in end demand. That matters because in med-tech capital equipment, a “better EBIT on worse orders” setup tends to lag in valuation until orders inflect; until then, the market often treats the improvement as quality-adjusted but not yet durable.

The second-order issue is pipeline timing. A sharp order miss in a business with long sales cycles can create a false sense of stability in the next 1-2 quarters if hospitals delay, then catch up; alternatively, it can foreshadow a softer FY27 if budget cycles have slipped. The fact that FX aided/ hurt lines in opposite directions also means consensus may be overestimating operating leverage: if currencies normalize, headline growth can improve while gross margin gives some back, limiting multiple expansion.

The balance-sheet and cash-flow progress likely matter more than the quarter’s P&L. Net debt down and stronger cash conversion reduce near-term financing risk, which can support the dividend and lower equity downside, but they do not by themselves solve the core issue: whether the installed base can generate enough replacement demand to sustain mid-single-digit constant-currency growth. The market is probably underpricing how much of the near-term upside is already embedded in the cost-reset narrative, while underappreciating the risk that FY27 guidance proves conservative if order weakness persists.

Contrarian read: this is not a turnaround to chase aggressively after a single quarter; it is a “show me the orders” setup. The most interesting window is likely 1-2 quarters out, when cost savings are already in the run-rate but revenue visibility either validates or breaks the thesis. If orders stabilize, the operating leverage could re-rate sharply; if not, the stock can drift lower even as reported margins remain respectable.

Key Decisions for Investors

• Stay neutral-to-slightly short EKTAb on rallies: use any post-earnings strength to fade until order intake shows at least 1 quarter of sequential stabilization; risk/reward favors limited upside without pipeline confirmation.
• For tactical upside, buy 3-6 month calls only as a catalyst trade into the next order update; structure as a call spread to cap premium bleed because the stock likely needs proof of demand, not just cost discipline.
• Pair trade: long higher-quality healthcare equipment names with stronger recurring revenue exposure versus short EKTAb; this isolates execution-risk dispersion and should work if the market continues rewarding visibility over margin repair.
• If you are already long, hedge with a tight downside collar into FY27 guidance risk; the main threat is not another earnings beat, but a second-order order slowdown that forces the market to reprice growth multiple compression.